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Abstract 
Plasmablastic  lymphoma  is  a  rare  and
aggressive  malignancy  strongly  associated
with HIV infection. The refractory/relapsed dis-
ease rate is high, and the survival rate is char-
acteristically  poor.  There  are  no  satisfactory
salvage regimens for relapsed cases. We suc-
cessfully performed autologous stem cell trans-
plantation  using  a  regimen  consisting  of
MCNU  (ranimustine),  etoposide,  cytarabine,
and  melphalan  in  a  Japanese  patient  with
relapsed AIDS-related plasmablastic lymphoma
of the oral cavity. Highly active antiretroviral
therapy  continued  during  the  therapy.
Therapy-related toxicity was tolerable, and a
total of 40 Gy of irradiation was administered
after autologous stem cell transplantation. The
patient has remained in complete remission
for 16 months since transplantation.
Introduction
Plasmablastic  lymphoma  (PBL)  was  pro-
posed in 1997 as a new distinct subtype of dif-
fuse large B-cell lymphoma (DLBCL).1 PBL has
a strong predilection for the oral cavity of HIV-
positive patients, predominantly in males. The
response duration is generally short, and the
refractory/relapsed  disease  rate  is  high.2,3
Previously, we reported that a MEAM [MCNU
(ranimustine), etoposide, cytarabine, melpha-
lan] regimen with autologous stem cell trans-
plantation (ASCT) was effective and well toler-
ated in 3 patients with refractory or relapsed
AIDS-related  lymphoma,  even  though  the
patients  were  infected  with  HIV.4 Here,  we
report  a  case  of  relapsed  PBL  treated  with
high-dose chemotherapy using a MEAM regi-
men followed by ASCT. 
Case Report
A 51-year-old Japanese man was diagnosed
with HIV infection 8 years previously present-
ed with night sweats, fever, weight loss, and a
gingival  ulcer.  Gingival  biopsy  showed  PBL
[LCA+, CD20–, CD79a–, CD38+, CD138+, MUM-
1+,  CD30  (partially+),  CD10–,  CD3–,  CD5–,
CD56–,  IgG+,  IgA–,  IgM–,  lambda+,  kappa–,
EBER-ISH+, LMP-1–, and HHV-8 LANA-1 (laten-
cy-associated nuclear antigen-1)–, Mib-1 index
40-90%; Figure 1], and computed tomography
(CT) confirmed stage IBE PBL. The patient’s
performance status was 1, and his serum LDH
level  was  above  normal.  No  bone  marrow
involvement was detected in the biopsy sam-
ple.  His  age-adjusted  IPI  (International
Prognostic Index) was a low intermediate. The
patient’s  HIV  viral  load  was  less  than  50
copies/mL, and his CD4 count was 520 cells/mL.
The  patient  was  treated  with  3  courses  of
CHOP  (cyclophosphamide,  adriamycin,  vin-
cristine, and prednisolone every 21 days, but
not given G-CSF routinely), 36 Gy of involved-
field radiation, and highly active antiretroviral
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Figure 1. Pathologic findings in the oral cavity (× 400). (A) Hematoxylin and eosin stain-
ing showing large cells with plasmablastic morphology. (B) The cells were negative for
CD20. (C) The cells expressed CD138, which is a plasma cell-related antigen. (D) EBV-
encoded RNA in situ hybridization (EBER-ISH) was positive.[page 34] [Rare Tumors 2011; 3:e11]
therapy  (HAART)  with  abacavir/lamivudine/
nelfinavir  concurrently.  He  achieved  a  com-
plete remission (CR) confirmed by a CT scan
and was followed up at our outpatient clinic for
1  year  after  the  completion  of  treatment.
However, the patient subsequently discontin-
ued regular visits and HAART. Two years later,
he developed an oral cavity tumor (Figure 2)
and was readmitted to our hospital. A CT scan
showed a gingival tumor with destruction of
the  maxillary  bone.  A  fluorodeoxyglucose
positron  emission  tomography  (FDG-PET)
scan (Figure 3a) showed increased uptake of
FDG in the tumor lesion. The initial diagnosis
was confirmed by a biopsy. The patient’s HIV
viral load was 1.2×105 copies/mL and his CD4
count was 90 cells/mL at the time of relapse.
First, the patient was administered modified-
ESHAP  (etoposide,  methylprednisolone,
cytarabine,  and  carboplatin)  as  salvage
chemotherapy,  but  there  was  no  significant
change in the tumor lesion after one course of
modified-ESHAP. Next, he was treated with two
courses  of  ICE  (ifosfamide,  carboplatin,  and
etoposide),  and  a  reduction  in  tumor  was
achieved. We performed intrathecal adminis-
tration of 15 mg methotrexate and 20 mg pred-
nisolone  on  the  day  preceding  each  course.
HAART  with  abacavir/lamivudine/raltegravir
was  administered  concurrently  with  the
chemotherapy. He was also treated with pro-
phylactic agents such as sulbactam/ampicillin
for aerobic and anaerobic bacteria in his oral
cavity, acyclovir for herpes simplex and zoster,
fluconazole for fungal infection, sulfamethoxa-
zole/trimethoprim  for  Pneumocystis  jiroveci
(discontinued on day 1 of ASCT and restarted
when  the  engraftment  was  confirmed),  and
azithromycin for Mycobacterium avium-intra-
cellulare complex (MAC). At the time of hema-
tological  recovery  from  modified-ESHAP,  a
CD34-positive cell count of 28.3×106 cells/kg
was obtained by G-CSF (2.5 mg/kg lenograstim
subcutaneously every 12 hours for 6 days). The
patient achieved a partial response (PR) after
completion of salvage therapy, and he was sub-
sequently treated with MEAM followed by infu-
sion of CD34+ cells at 4.7×106 cells/kg (Table
1).  Nine  days  after  transplantation,  he
achieved complete hematological recovery, and
the regimen-related toxicity was mild showing
grade 1 nausea, grade 2 diarrhea, and grade 3
febrile neutropenia. HIV control was optimal
throughout transplantation, and the CD4 count
rapidly increased after stem cell transplanta-
tion. At the time of relapse, the CD4 count was
less than 100 cells/µL; however, 1 year after
transplantation it increased to more than 400
cells/µl (Figure 4). The patient achieved CR
after ASCT (Figure 3b). Subsequently, 40 Gy of
irradiation was administered to the oral cavity
and the left maxillary sinus. The patient has
remained in complete remission for 16 months
after transplantation.
Discussion
Plasmablastic lymphoma is a distinctive B-
cell neoplasm that manifests diffuse prolifera-
tion of large atypical lymphoid cells, most of
which resemble B-immunoblasts and have the
immunophenotype  of  plasma  cells.5 PBL  is
uncommon and accounts for 2.6% of all AIDS-
related lymphomas.6 The clinical course is very
aggressive. A retrospective analysis of 112 pub-
lished  cases  showed  that  the  refractory/
relapsed disease rate was 54%; mortality rate
was 53%, and the median overall survival rate
was 15 months.3 Initially, our patient achieved
a  CR  by  chemoradiotherapy  combined  with
HAART.  However,  the  lymphoma  relapsed  20
months  after  discontinuation  of  HAART.  A
meta-analysis  showed  that  the  prognosis  of
PBL  was  statistically  better  in  patients  who
received HAART in addition to chemotherapy
and/or  radiotherapy  than  in  patients  who
received  chemotherapy  and/or  radiotherapy
alone.7 Francischini et al. reported a case of
PBL that recurred after interruption of HAART
thus  substantiating  the  findings.8 Immuno  -
logic and virologic control with HAART may be
beneficial for treating PBL and may possibly
maintain continued CR.9 In our case, HAART
was initiated with chemotherapy concurrently.
We avoided the use of zidovudine and stavu-
dine because of its associated bone marrow
toxicity and neurotoxicity. The use of protease
inhibitors was also avoided because of their
inhibitory effect on CYP3A4. No serious side
effects associated with HAART were noted in
this patient.
Epstein-Barr virus (EBV) is identified in the
neoplastic cells of approximately 40% of HIV-
related  lymphoma  cases,  and  human  her-
pesvirus  (HHV)-8  is  specifically  associated
with  primary  effusion  lymphoma  and
Castleman  disease.10 We  detected  the  EBV
genome in atypical cells by in situ hybridiza-
tion, and it is considered to play a vital role in
the pathogenesis of PBL.1 Our case was nega-
tive for HHV-8 LANA-1. Previous studies have
shown the absence of HHV-8 in oral PBL cells,
but Cioc et al. reported the presence of HHV-8
in oral PBL cells using reverse transcriptase in
situ PCR  method.11 It  is  possible  that  some
cases of PBL are associated with HHV-8.
Recently,  high-dose  chemotherapy  and
ASCT  as  a  salvage  therapy  for  relapsed  or
Case Report
Figure 2. Clinical appearance of the lesion
at relapse.
Figure 3. (a) Fluorodeoxyglucose positron
emission tomography scan of the oral cav-
ity prior to salvage therapy. FDG uptake
was  shown  in  the  tumor.  (b)
Fluorodeoxyglucose  positron  emission
tomography scan of the oral cavity after
autologous  stem  cell  transplantation.  No
abnormal  uptake  was  present  in  this
region.
a
b
Table 1. MEAM regimen.
Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 Day 0
MCNU 300 mg/m2 ô ￿
Etoposide 200 mg/m2 ôôô ￿
Cytarabine 200 mg/m2 ôôô ￿￿ ￿
L-PAM 140 mg/m2 ô￿ SCTi
Figure 4. Transition of CD4+ cell counts
(/µL) before and after autologous stem cell
transplantation.
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refractory AIDS-related lymphoma was shown
to  be  feasible  and  effective.12,13 However,  its
role in relapsed AIDS-related PBL was unclear.
We found that at least 7 cases of AIDS-related
PBL were treated with ASCT,3,12,14-17but the effi-
cacy of ASCT has not yet been analyzed. In this
case, we performed ASCT using a MEAM regi-
men based on a BEAM regimen by replacing
BCNU  (carmustine)  with  MCNU.  The  regi-
men-related  toxicity  was  mild.  The  patient
developed febrile neutropenia but it was not
caused  by  Pneumocystis  pneumonia,  MAC
infection, or any other serious infection. He
had an ulcer with necrotic tissue in his oral
cavity which seemed to be related to a severe
infection. The use of sulbactum/ampicillin as
prophylaxis  was  effective.  High-dose  chemo  -
therapy using a MEAM regimen with HAART
followed by ASCT seemed to be well tolerated.
Re et al. showed that a low CD4 count, a
poor  performance  status,  and  bone  marrow
involvement were negative prognostic factors
in patients treated with ASCT.16 In our patient,
the CD4 count was less than 100 cells/mL, the
performance status was 1, and no bone marrow
involvement  was  detected  at  the  time  of
relapse. The patient is currently alive with no
relapse or major opportunistic infection. The
CD4 count increased rapidly after transplanta-
tion.  Recently,  some  studies  showed  that
immune recovery after ASCT for HIV-related
lymphoma was similar to that observed in HIV-
negative patients.18,19 High-dose chemotherapy
followed  by  ASCT  for  relapsed  AIDS-related
PBL seems to be feasible and effective.
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